Orion Corporation

Forendo Pharma Ltd

Organon R&d Finland Oy

Organon R&d Finland Ltd

Tero Linnanen

Gerd Wohlfahrt

Subhendu Mukherjee

Ravi Kotrabasaiah Ujjinamatada

Pasi Koskimies

Srinivas Nanduri

Leena Hirvelä

Srinivasan Rajagopalan

Marjo Hakola

Camilla Stjernschantz

Leena Hirvela

Susanta Samajdar

Mikko Kalervo Mäkelä

Chandrasekhar Abbineni

Mikko K Makela

Tuula Koskelainen

Antti Pohjakallio

Anna Minkkilä

Mikko Mäkelä

Kaisa Illikainen

Anna Minkkila

Olli PENTIKÄINEN

Anna MinkkilÄ

Prasad Appukuttan

Karthikeyan Narasingapuram Arumugam

Shyla George

The invention relates to compounds of formula (II), and pharmaceutically acceptable salts thereof,wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

Therapeutically active steroidal derivatives

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Protein kinase inhibitors

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives of formula (I)  in which Cy, R, R, R, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

Spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives as bromodomain inhibitors

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Compounds of formula (I), wherein X and R-R, are as defined in the claims, exhibit alpha2 agonistic activity and thus are useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.

Alpha2 adrenoceptor agonists

Growing community of inventors

Tuusula, Finland

Tero Linnanen